In the market the company is trading up by 4.64% percent from yesterday’s close and is one of the top gainers in today’s market. More than 120,340 shares have changed hands.
Shares are trading at $5.19 which is well above the 50 day moving average which is $4.15 and which is significantly above the 200 day moving average of $4.56. The 50 day moving average was up $1.04 or +25.17% and the 200 day average moved up $0.63.
Short traders are feeling a little more bearish on Fluidigm Corporation of late as implied by the increase in short interest. The firm had a rise in short interest of 10.63% as of the latest report on August 31, 2017. Short shares grew from 2,840,959 to 3,142,831 over that timeframe. The days to cover increased to 15.0 and the short interest percentage is 0.11% as of August 31.
Here is a rundown on some insider market activity for Fluidigm Corporation (NASDAQ:FLDM). Chief Commercial Officer Steven Mcphail bought 20,000 shares at an average price of $3.00 on August 8th. That brings Mcphail’s holdings to $83,526 per an SEC filing yesterday. Stephen Christopher Linthwaite, President & CEO disclosed the purchase of 45,000 shares. The shares were bought on August 8th for an average price of $2.66. The President & CEO now owns $284,559 of the stock per the Form 4 SEC filing.
CHIEF FINANCIAL OFFICER Vikram Jog disclosed the purchase of 50,000 shares of FLDM stock. The shares were purchased at an average price of $2.71. Jog now owns $141,085 of the stock according to the SEC filing.
These firms have modified their investment in FLDM. As of the end of the quarter Neuberger Berman Group LLC had sold a total of 73,027 shares trimming its stake by 3.8%. The value of the investment in (FLDM) decreased from $10,950,000 to $7,480,000 decreasing 31.7% since the last quarter. Healthcare Value Capital, LLC reduced its position by selling 125,000 shares a decrease of 45.5% as of 06/30/2017. Healthcare Value Capital, LLC now controls 150,000 shares worth $606,000. The total value of its holdings decreased 61.3%.
As of quarter end Pdt Partners, LLC had acquired 9,800 shares growing its position 56.0%. The value of the company’s investment in Fluidigm Corporation went from $100,000 to $110,000 a change of $10,000 quarter over quarter. Two Sigma Advisers, Lp divested its stake by shedding 2,088 shares a decrease of 16.5% in the quarter. Two Sigma Advisers, Lp now holds 10,600 shares valued at $43,000. The value of the position overall is down by 40.3%.
In the last earnings report the EPS was $-2.45 and is expected to be $-2.13 for the current year with 29,414,000 shares presently outstanding. Next quarter’s EPS is forecasted at $-0.43 with next year’s EPS projected to be $-1.61.
Fluidigm Corporation, launched on March 29, 2007, creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Business’s core microfluidics and mass cytometry technologies. The Company sells instruments and consumables, including integrated fluidic circuits, assays and reagents, to academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology (Ag-Bio) companies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. The Company offers various types of products, which include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents..